I'm very weak on the treatment strategies for CRC.
However, isn't best supportive care usually reserved for patients with no other approved treatment options? That would place this trial in a last-ditch population. That would also be consistent with the description provided at your link: patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC.